Allergan Plc (AGN)
$166.47 0.74 (0.45%)
18:29 EDT AGN Stock Quote Delayed 15 Minutes
Previous Close $166.47
Market Cap 65.33B
PE Ratio -32.45
Volume (Avg. Vol.) 7.82M
Day's Range 165.42 - 167.29
52-Week Range 114.27 - 197.00
Dividend & Yield 2.88 (1.73%)
AGN Stock Predictions, Articles, and Allergan Plc News
- From InvestorPlace
- From the Web
These undervalued stocks have been hit hard lately, but they still have what it takes to make a comeback, making them solid stocks to buy.
After six straight sessions of losses, it was a welcomed sight to see stocks rally on Tuesday. Here's what happened on the stock market today.
This morning, I am recommending a bullish trade on AbbVie, Inc. (NYSE:ABBV), the biopharmaceutical company.
Trump says that Facebook and Alphabet should be sued, while Micron surged on earnings. Semiconductors got a big boost in the Nasdaq today as well.
Options trading was buzzing in AbbVie, FedEx and Micron Tuesday. Here are the metrics that matter moving forward.
The stock charts of TSN, STT and LEN are headed into the midpoint of the week on the verge of major turns.
Biotech rallied on a $63 billion deal between AbbVie and Allergan. But other than that, it was a tough day for the Nasdaq today.
AbbVie is buying Allergan, FedEx and Blackberry are reporting earnings and Microsoft is on the move. Here are our top stock trades.
News of an AbbVie-Allergan deal has AGG stock heading higher on Tuesday with plans for the former company to acquire the latter.
Allergan looks to still be in a downtrend, while Etsy stock is fighting with resistance at $70 and Boeing hurdles the 50-day moving average.
The stock charts of Centurylink, Allergan and Charles Schwab are prepared to get the new trading week started with a bang.
Wall Street analysts see significant upside in these 10 stocks to buy. And all ten have other reasons for optimism as well.
Government is scrutinizing the drug development and approval process and creating uncertainties among biotech stocks. Time to buy?
Allergen needs to win back investors as the company continues to look for new drug products. AGN stock is stuck in a narrow trading range.
AMZN, TAP, ALGN and AGN are just some of the stocks on the rise as we head into the second quarter of the year.
As Goldman Sachs moves away from the strong balance sheet investing strategy, here are 6 new stocks to buy.
Traders are looking for progress in U.S.-China trade. If they don't find it, or worse news arrives, beware these blue-chip stocks!
Everything Jim Cramer said about the stock market on 'Mad Money,' including the week ahead, iPhone sales, AbbVie vs. Bristol-Myers and Zscaler CEO
Navellier RatingsPowered by Portfolio Grader
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!